Sign up for our Oncology Central weekly news round-up

Direct drug delivery and electroporation for internal tumors: a new platform developed by OncoSec

Written by Keir LoIacono, John Rodriguez, Daniel J. O’Connor, James R. Nitzkorski, Christopher G. Twitty
Emerging technologies For clinicians Immuno-oncology Industry and business Opinion

OncoSec (CA, USA) has developed a therapeutic platform for the reversible electroporation of plasmid DNA that uses patients’ own tumors to produce a potent, yet safe immunotherapy, whereby sustained intracellular release of the pro-inflammatory cytokine IL-12 transforms immunosuppressed tumors into immunologically active lesions through coordinated innate and adaptive immunity. Click here to find out more about this platform.